STOCK TITAN

Syndax Pharmaceuticals (SNDX) Stock News, Jul-Oct 2023

SNDX NASDAQ

Syndax Pharmaceuticals reports developments as a commercial-stage biopharmaceutical company advancing cancer therapies. Company updates center on Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 receptor.

Recurring news includes quarterly financial results, product revenue for Revuforj and Niktimvo, collaboration revenue from Niktimvo commercialization with Incyte, clinical data presentations in acute leukemia, chronic graft-versus-host disease and related indications, FDA-related product updates, investor conference activity and inducement equity grants under Nasdaq listing rules.

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.02%
Tags
conferences clinical trial
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.97%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.62%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.48%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.90%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.40%
Tags
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.10%
Tags
none

FAQ

What is the current stock price of Syndax Pharmaceuticals (SNDX)?

Syndax Pharmaceuticals (SNDX) last closed at $9.20.

What is the market cap of Syndax Pharmaceuticals (SNDX)?

The market cap of Syndax Pharmaceuticals (SNDX) is approximately $828.3M.